‘Significant step’ made in creating breakthrough blood test to detect brain tumours - A new blood test is being developed by ...

At present, diagnosing and treating patients can be complex ...

Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant ...

Honing in on four markers for effective, patient-specific devices to combat glioblastoma.

Phase 1 clinical trials evaluate the safety and dosage of proposed new treatments. Further research is needed to test the oncolytic virus therapy’s effectiveness and side effects. Work also continues ...

Akeso (SEHK:9926) reported long term survival data from a Phase II study of cadonilimab in advanced cervical cancer, highlighting durable benefits in a setting with limited treatment options. The ...

Researchers in China have developed magnetically controlled microrobots made from diatoms for the treatment of glioblastoma using photodynamic therapy. These microrobots exhibit excellent magnetic ...

Glioblastoma is the most aggressive and deadliest form of brain cancer. Most patients survive only about a year after diagnosis, and just 5% make it to five years. Dr. Minesh P. Mehta is leading the ...

Telix has resubmitted the NDA with the additional data requested by the FDA. The Company believes, based on the Type A meeting and ongoing consultation with the FDA, that the additional data and ...

Alex Warwick was told over and over that his symptoms were due to stress or health anxiety from being in medical school ...